c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
文献类型：期刊论文
| 作者 | Liu, Hongyan; Ai, Jing ; Shen, Aijun; Chen, Yi; Wang, Xinyi; Peng, Xia; Chen, Hui; Shen, Yanyan; Huang, Min; Ding, Jian
|
| 刊名 | CLINICAL CANCER RESEARCH
 |
| 出版日期 | 2017-02 |
| 卷号 | 23期号:4页码:974-984 |
| ISSN号 | 1078-0432 |
| DOI | 10.1158/1078-0432.CCR-15-2448 |
| 文献子类 | Article |
| 英文摘要 | Purpose: Lately, emerging evidence has suggested that oncogenic kinases are associated with specific downstream effectors to govern tumor growth, suggesting potential translational values in kinase-targeted cancer therapy. Tyrosine kinase FGFR, which is aberrant in various cancer types, is one of the most investigated kinases in molecularly targeted cancer therapy. Herein, we investigated whether there exists key downstream effector(s) that converges FGFR signaling and determines the therapeutic response of FGFR-targeted therapy. Experimental Design: A range of assays was used to assess the role of c-Myc in FGFR aberrant cancers and its translational relevance in FGFR-targeted therapy, including assessment of drug sensitivity using cell viability assay, signaling transduction profiling using immunoblotting, and in vivo antitumor efficacy using cancer cell line-based xenografts and patient-derived xenografts models. Results: We discovered that c-Myc functioned as the key downstream effector that preceded FGFR-MEK/ERK signaling in FGFR aberrant cancer. Disruption of c-Myc overrode the cell proliferation driven by constitutively active FGFR. FGFR inhibition in FGFR-addicted cancer facilitated c-Myc degradation via phosphorylating c-Myc at threonine 58. Ectopic expression of undegradable c-Myc mutant conferred resistance to FGFR inhibition both in vitro and in vivo. c-Myc level alteration stringently determined the response to FGFR inhibitors, as demonstrated in FGFR-responsive cancer subset, as well as cancers bearing acquired or de novo resistance to FGFR inhibition. Conclusions: This study reveals a stringent association between FGFR and the downstream effector c-Myc in FGFR-dependent cancers, and suggests the potential therapeutic value of c-Myc in FGFR-targeted cancer therapy. (C)2016 AACR. |
| WOS关键词 | CELL-CYCLE ARREST ; BREAST-CANCER ; LUNG-CANCER ; MAMMALIAN TARGET ; EXPRESSION ; VEMURAFENIB ; SENSITIVITY ; RESISTANCE ; ADDICTION ; PHENOTYPE |
| 资助项目 | National Program on Key Basic Research Project of China[2012CB910704] ; National Key Sci-Tech Project[2012ZX09301001-007] ; Natural Science Foundation of China[81321092] ; Natural Science Foundation of China[81473243] ; Natural Science Foundation of China[81222049] ; Natural Science Foundation of China[81402966] ; Chinese Academy of Sciences[XDA12020101] ; Youth Innovation Promotion Association[00000000] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000393885700012 |
| 出版者 | AMER ASSOC CANCER RESEARCH |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/275650]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Huang, Min; Ding, Jian; Geng, Meiyu |
| 作者单位 | Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Hongyan,Ai, Jing,Shen, Aijun,et al. c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors[J]. CLINICAL CANCER RESEARCH,2017,23(4):974-984. |
| APA | Liu, Hongyan.,Ai, Jing.,Shen, Aijun.,Chen, Yi.,Wang, Xinyi.,...&Geng, Meiyu.(2017).c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.CLINICAL CANCER RESEARCH,23(4),974-984. |
| MLA | Liu, Hongyan,et al."c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors".CLINICAL CANCER RESEARCH 23.4(2017):974-984. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。